TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pro Medicus Limited ( (AU:PME) ) has shared an update.
Pro Medicus Limited has secured a $25 million, 7-year contract with BayCare, a leading healthcare system in Florida, to implement its Visage 7 Open Archive in the cloud. This deal extends their existing contract to a full-stack solution, enhancing Pro Medicus’s expansion into the North American IDN market and offering potential financial upside through a transaction-based model.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a leading healthcare informatics company founded in 1983, providing a comprehensive range of medical imaging software and services to hospitals, imaging centers, and healthcare groups globally. The company, which acquired Visage Imaging in 2009, offers a suite of products under the Visage 7 brand, known for its ultra-fast, clinically rich, and scalable platform that can be implemented in both public and private cloud environments. Pro Medicus is recognized for its end-to-end healthcare imaging solutions, including RIS, PACS, AI, and e-health offerings, with offices in Melbourne, Berlin, and San Diego.
YTD Price Performance: 6.77%
Average Trading Volume: 172,372
Technical Sentiment Signal: Buy
Current Market Cap: A$27.86B
For an in-depth examination of PME stock, go to TipRanks’ Overview page.